Busulfan, Melphalan, and Bortezomib Compared to Melphalan as a High Dose Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow Up of a Novel High Dose Regimen

Melphalan at a dose of 200 mg/m(2) (MEL200) remains the standard high dose therapy before autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Intensifying the high dose regimen has shown promising results. We report here 7-year follow up of our novel high dose regimen of busulfan...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: Hagen, Patrick, D’Souza, Anita, Hari, Parameswaran, Davila, Omar, Zhang, Mei-Jie, Vesole, David H., Smith, Scott E., Rodriguez, Tulio E, Stiff, Patrick J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7786301/
https://ncbi.nlm.nih.gov/pubmed/32865474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1811275
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi